Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Prostate Cancer Metastatic × Genitourinary × 30 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 321 Urinary Bladder Neoplasms 98 Carcinoma, Renal Cell 96 Carcinoma, Transitional Cell 48 Neoplasms 47 Breast Neoplasms 45 Kidney Neoplasms 42 Ovarian Neoplasms 41 Colorectal Neoplasms 33 Carcinoma, Non-Small-Cell Lung 33 Melanoma 29 Neoplasm Metastasis 26 Endometrial Neoplasms 25 Lung Neoplasms 24 Pancreatic Neoplasms 22 Non-Muscle Invasive Bladder Neoplasms 22 Uterine Cervical Neoplasms 18 Stomach Neoplasms 17 Sarcoma 16 Esophageal Neoplasms 15 Adenocarcinoma 14 Triple Negative Breast Neoplasms 13 Squamous Cell Carcinoma of Head and Neck 12 Prostatic Neoplasms, Castration-Resistant 12 Carcinoma, Hepatocellular 11 Head and Neck Neoplasms 10 Urethral Neoplasms 9 Disease 9 Clear-cell metastatic renal cell carcinoma 9 Urologic Neoplasms 8

Interventions

fludrocortisone acetate 1 enzalutamide 1 Prednisone 1 Hydrocortisone 1 Dexamethasone 1 Abiraterone Acetate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06136624 2026-03-11

OMAHA-003

Merck Sharp & Dohme LLC

Phase 3 Recruiting

Prostate Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡